Daxor (DXR) Stock Price, News & Analysis

Company Overview

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting. The company offers training and technical support to hospital laboratories and specialty clinics, ensuring that staff are properly instructed in isotope handling, system operation and result interpretation. Through ongoing research collaborations, Daxor continuously evaluates new protocols and software enhancements to improve diagnostic performance and workflow efficiency.

Headquartered in New York, Daxor serves healthcare providers in North America and has established distribution partnerships in Europe, Asia‐Pacific and select emerging markets. Its solutions are used by major university medical centers, community hospitals and research institutions to inform decisions on blood transfusion, fluid management and therapeutic intervention. The company’s management team brings decades of experience in medical technology commercialization, regulatory affairs and laboratory operations, positioning Daxor to expand its global footprint and address evolving needs in patient blood management.

Key Stats

• Today's Range: $10.20 to $10.92
• 50-Day Range: $8.79 to $11.89
• 52-Week Range: $7.57 to $14.76
• Volume: 2,811 shs
• Average Volume: 9,255 shs
• Market Capitalization: $53.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Daxor Stock Analysis - MarketRank™

Daxor scored higher than 34% of companies evaluated by MarketBeat, and ranked 711th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Daxor has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Daxor has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.17% of the float of Daxor has been sold short.

Short Interest Ratio / Days to Cover

Daxor has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daxor has recently increased by 10.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Daxor does not currently pay a dividend.

Dividend Growth

Daxor does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for DXR on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $9,070.00 in company stock, which represents 0.0170% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Daxor insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,070.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

59.50% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.34% of the stock of Daxor is held by institutions.

Company Calendar

• Last Earnings: 3/02/2026
• Today: 5/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:DXR
• Previous Symbol: NYSEAMERICAN:DXR
• CIK: 27367
• Web: www.daxor.com
• Phone: 212-244-0555
• Fax: 212-244-0806
• Employees: 37
• Year Founded: 1970

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 5,040,000
• Free Float: 2,041,000
• Market Cap: $53.30 million
• Optionable: Not Optionable
• Beta: 0.29